Author: Ravi Shankar

News Summary:

• Bolt with Lucid, Mercedes-Benz, Volkswagen Commercial Vehicles and Einride are showcasing selected autonomous-mobility use cases on the NVIDIA Hyperion computing platform, demonstrating potential applications for level 3 and level 4 vehicles as well as future robotaxi fleets, with Volvo Cars adopting Hyperion and NVIDIA Alpamayo Stack for safe automated driving.
• NVIDIA introduces Halos SAFE, a new framework within the NVIDIA Halos safety system, which combines simulation and physical testing to help developers generate measurable, traceable AV safety evidence.
• NVIDIA announces Alpamayo 2 Edge, Alpamayo Agentic Factory and new Cosmos 3 Nano model variants to help developers build, customize and evaluate autonomous-driving for diverse vehicles, operating conditions and regions.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — GTC Berlin — NVIDIA today announced that leading automakers in Europe and mobility providers, including Bolt with Lucid, Mercedes-Benz, Volkswagen Commercial Vehicles and Einride, are showcasing selected autonomous-mobility use cases on the NVIDIA Hyperion computing platform, demonstrating potential applications for level 3 and level 4 vehicles as well as future robotaxi fleets.

In addition, Volvo Cars is adopting Hyperion and NVIDIA Alpamayo Stack software for safe automated driving. NVIDIA also introduced new AI and safety technologies to help developers build, validate and deploy autonomous vehicles (AVs) at scale.

Autonomous transportation represents a multitrillion-dollar opportunity, with robotaxis leading the move to commercial level 4 deployment. NVIDIA Hyperion and the NVIDIA Halos full-stack safety system give automakers and mobility providers the computing performance, safety foundation and long-term support to bring AVs and robotaxi fleets to market at scale.

“Robotaxis are the first mass-market application of robotics and physical AI, reinventing how people and goods move,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA Hyperion, together with our Halos safety operating system, gives our partners a full-stack robotaxi platform designed to achieve full autonomy and the highest levels of safety, bringing us closer to a future where everything that moves is autonomous.”

Mobility Leaders in Europe Build on NVIDIA Hyperion
Automakers and mobility providers in Europe are pursuing various paths to autonomy, from passenger vehicles and robotaxi fleets to autonomous freight trucks. NVIDIA Hyperion’s modular architecture supports all of these programs, compatible with NVIDIA Alpamayo Stack autonomous driving software as well as partners’ own driving software.

Bolt has selected NVIDIA Alpamayo Stack for its European robotaxi program, beginning with future Lucid vehicles built on Hyperion. Bolt and NVIDIA will adapt the software for European roads and integrate it into vehicles from multiple manufacturers, combining NVIDIA’s driving and safety technologies with Bolt’s fleet-management systems, operations and local market expertise.

Bolt plans to begin gathering real-world driving data to support the development and validation of the autonomous driving technology — subject to regulatory approval — in Madrid in 2027, with Germany being a priority for future deployment as part of a planned European rollout of at least 25,000 level 4-capable future Lucid vehicles built on NVIDIA Hyperion.

At GTC Berlin, Volkswagen Commercial Vehicles is presenting its autonomous ID. Buzz AD vehicle platform with Hyperion to support multiple autonomous-driving systems. Hyperion provides a common computing and sensor architecture designed to simplify integration and validation, helping developers and mobility operators bring robotaxi and commercial transport services to market.

Volvo Cars is combining its industry-leading vehicle safety systems and engineering expertise with Hyperion, Halos OS and Alpamayo Stack to enable future Volvo cars to safely navigate complex real-world environments from door to door.

Mercedes-Benz is extending its partnership with NVIDIA on Hyperion and Alpamayo Stack to support the development of the automaker’s L3 and L4 capabilities. The company also announced that MB.DRIVE ASSIST PRO, developed in partnership with NVIDIA, will soon get approval for urban point-to-point urban driver assistance in Germany, helping drivers navigate journeys through complex city traffic.

Beyond passenger vehicles and robotaxis, Einride is building its next-generation Einride Driver on Hyperion for autonomous freight trucks, using Halos, Alpamayo and NVIDIA Cosmos™ open world models to develop and validate its driving system, while TIER IV and the Technical University of Munich plan to integrate Hyperion to develop and validate systems for autonomous public transportation in Germany.

NVIDIA technology and manufacturing partners are also helping expand the AV ecosystem, with Aptiv, Valeo and Schaeffler building Hyperion-based computing platforms that can be integrated by vehicle manufacturers for L4 AVs and robotaxis.

Scaling Safe Autonomy With NVIDIA Halos
Halos provides the safety foundation for NVIDIA’s AV platform, bringing together AI computing, safety software and validation from development through deployment.

To give developers repeatable ways to evaluate driving behavior and simulation accuracy, NVIDIA today introduced Halos SAFE — the Safety Assurance Framework for Evaluation — with dSPACE, IVEX and TÜV Rheinland collaborating on evaluation workflows. Halos SAFE connects simulation, software- and hardware-in-the-loop evaluation, on-road testing and fleet monitoring through defined scenarios, tests and measurable performance criteria to generate traceable safety evidence that supports deployment.

The Halos SAFE ecosystem also includes JLR, Mercedes-Benz, Volvo Cars, 51Sim, aiMotive, AVL, Deepen AI, Foretellix and Synopsys.

Accelerating AV Development
Developing AVs means teaching AI to handle the diversity of real-world driving, then bringing that intelligence into the vehicle. NVIDIA’s latest models, tools and blueprints help developers prepare driving data, improve models and evaluate performance:

• Alpamayo 2 Edge, a 2-billion-parameter reasoning model built on NVIDIA Cosmos 3 Edge’s NVIDIA Nemotron™-based foundation, is optimized for the NVIDIA DRIVE AGX Thor™ platform and designed to run at 10Hz for in-vehicle scene understanding and motion planning.
• AlpaJudge, a human-calibrated evaluation and reward model, scores driving explanations to assess reasoning quality, filter weak annotations and reduce manual review of training data.
• Foundation4D labels multicamera video without lidar input, supporting perception-model training and NVIDIA Omniverse™ NuRec scene reconstruction.
• New Cosmos 3 Nano model variants expand synthetic data generation and closed-loop simulation for autonomous driving through synchronized multiview, multi-camera and lidar generation across diverse driving scenarios.
• Cosmos Data Factory’s AV dataset-generation blueprint turns driving video and vehicle signals into curated, searchable, labeled data, using synthetic data to expand scenario coverage.
• Alpamayo Agentic Factory, an open blueprint expected to become available in early 2027, uses AI agents to connect data preparation, model post-training and simulation evaluation, reducing integration work.
• NVIDIA NIM™ microservices for Alpamayo 1.5 and NuRec Harmonizer deliver both models as optimized inference containers, giving AV reasoning and scene harmonization a simplified deployment path.

Uber and NVIDIA are developing a data factory powered by Cosmos to curate and process data for AV development. The effort is part of a broader partnership spanning AI development infrastructure, Hyperion-based vehicles and Uber’s global ride-hailing network.

Porsche is leading the development of a data flywheel workflow across Volkswagen Group brands through Voxel51, using NVIDIA Cosmos Data Factory and Omniverse NuRec on Microsoft Azure to turn fleet data into datasets and simulations for evaluating autonomous-driving models. This is expected to reduce repeated physical test drives by up to 90% and shorten development cycle duration by up to 85%.

Watch the GTC Berlin keynote from Huang and explore sessions.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Corporate Communications
NVIDIA Corporation
press@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners, and their plans to develop and deploy autonomous vehicles and robotaxi fleets, and related timing; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on NVIDIA’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, and other NVIDIA product and service names are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries and regions. Other company, product, and service names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6facbac6-d80f-4d4b-b166-891b08cf8ec4

 News Summary:

• NVIDIA and the UW Medicine Institute for Protein Design debut RFD4-Proteina, a new open model that combines programmable protein design with search capabilities, unlocking new frontiers in biology.
• Siemens Healthineers is advancing the next generation of adaptive radiotherapy, using NVIDIA intelligence to increase access to life-saving cancer care with agentic co-planning, patient-specific simulation and robotic control.
• Automata, Benchling, Biolevate, Boltz, Danaher, Hologen and Therna Biosciences are using the NVIDIA BioNeMo open platform to develop scientific agents that connect drug design, autonomous laboratories and biological discovery, helping researchers move from hypothesis to experiments faster.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — GTC Berlin—NVIDIA today announced collaborations with leading global healthcare and research organizations to advance protein design — including through a newly released open model, RFD4-Proteina — accelerate drug discovery and bring greater precision to cancer care.

Life sciences researchers must search vast biological design spaces and aim to shorten the cycle between computational design and laboratory testing to discover new medicines. Cancer care teams face a different challenge: translating complex imaging and treatment data into precise plans for each patient.

NVIDIA open models, accelerated computing and physical intelligence can help experts evaluate more possibilities faster, from designing new proteins to planning adaptive radiotherapy.

“Agentic and physical AI are opening new possibilities across medicine, from designing proteins and powering autonomous laboratories to improving personalized cancer care,” said Kimberly Powell, vice president of healthcare at NVIDIA. “Together with healthcare and life science leaders, we’re accelerating scientific discovery and advancing more precise, accessible care around the world.”

NVIDIA and the UW Institute for Protein Design Introduce RFD4-Proteina
Proteins are molecular tools that perform many of life’s essential tasks, and designing new versions could open paths to new medicines, diagnostics and industrial applications. But finding a protein capable of performing a designed function requires searching an immense range of possible designs.

NVIDIA and the UW Medicine Institute for Protein Design are debuting RFD4-Proteina, a new NVIDIA BioNeMo™ open model that combines programmable protein design with search capabilities.

The model generates targeted protein designs, enabling scientists and agents to search and refine designs using molecular inputs, constraints and scoring objectives. Potential applications include designing proteins to interrupt disease processes or detect signs of disease in diagnostic tests.

In testing reported in the research draft, RFD4-Proteina achieved higher computational design success rates and generation throughput than the evaluated baselines across four benchmark suites: protein binding, small-molecule binding, enzyme scaffolding and DNA binding. The model helps researchers explore and prioritize candidates for laboratory testing, where experiments establish how a design performs under tested conditions.

“We are moving from an era of discovering the proteins nature has made to one in which we can design entirely new ones,” said David Baker, 2024 Nobel Laureate in chemistry and director of the Institute for Protein Design at the University of Washington. “RFD4-Proteina expands what scientists can create, from proteins that could advance drug discovery to enzymes that break down pesticides. Making the model open will allow researchers around the world to build on these capabilities and pursue solutions once beyond the reach.”

RFD4-Proteina is available today through partners including Amazon Bio Discovery, Anthropic’s Claude Science, Benchling, Databricks, Google Cloud, Hugging Face, Nebius, OpenAI and Tamarind Bio, enabling researchers and developers to integrate the open protein design model into agent, cloud and scientific computing workflows.

Siemens Healthineers Advances Cancer Care With NVIDIA
Siemens Healthineers and NVIDIA are collaborating to develop the next generation of adaptive radiotherapy with agentic and robotic intelligence, combining imaging and oncology expertise with accelerated computing and simulation to simplify workflows and expand access to care.

By 2050, approximately 35 million people worldwide are projected to be diagnosed with cancer each year. Care teams face growing pressure to deliver precise, personalized treatment while managing limited specialist capacity. Greater efficiency can help expand access to care while maintaining the precision needed to deliver prescribed doses to tumors and protect surrounding healthy tissue.

Siemens Healthineers is working with NVIDIA to further develop adaptive radiotherapy through agentic co-planning, patient-specific simulation and real-time computing. NVIDIA Nemotron™ open foundation models are being explored to power agentic co-planning, with the aim of helping oncologists evaluate and refine personalized treatment strategies. The models could then be combined with NVIDIA CUDA^®-accelerated dose calculation for rapid patient-specific simulation and the NVIDIA Holoscan platform to connect live sensor data with AI and simulation to support adaptive treatment.

“Adaptive radiotherapy is built on a single principle: treatment should adapt to the patient, not the other way around,” said Arthur Kaindl, head of Varian, the Siemens Healthineers cancer-care business. “We’ve made important advances in precision and adaptation — most recently, with the launch of the Accela system. Our collaboration with NVIDIA builds on that progress, exploring how AI and real-time computing could give clinicians greater speed and insight to make informed decisions, adapt treatment with greater confidence and deliver personalized care to more patients.”

Scientific Agents Advance Drug Discovery and Development
Life sciences is one of the world’s most important scientific frontiers, with global scientific R&D reaching $3.8 trillion and annual pharmaceutical budgets approaching $300 billion.

Scientific agents and autonomous laboratories can help turn more of that investment into evidence, insight and, ultimately, new treatments by connecting design, experimentation and learning in a continuous cycle.

To accelerate discovery and free up scientists for work only they can do, research and laboratory technology companies are using NVIDIA BioNeMo — an open development platform that enables AI-driven biology and drug discovery — alongside Nemotron and other NVIDIA technologies to develop scientific agents and the specialized models and tools that connect drug design, scientific data and laboratory workflows:

• Benchling is grounding agents in experimental data, research context and connected scientific workflows.
• Biolevate is connecting biological data, specialized scientific tools and agentic reasoning across drug discovery and development.
• Boltz is developing specialized models and tools that scientific agents can use to predict molecular structures and design and evaluate candidates. It is also previewing a scientific agent to plan workflows, apply the right models and interpret results to guide the next experiment.
• Automata is connecting scientific agents with automated laboratory infrastructure so they can initiate experiments and capture structured, contextualized results through workflows.
• Genedata’s AI co-scientist will coordinate protein design and testing in the protein design foundry within Danaher’s autonomous lab. The workflow will incorporate RFD4-Proteina, helping scientists use experimental results to guide the next round of designs.
• Hologen is combining its large medicine models with NVIDIA Nemotron to build AI clinical scientists that help researchers turn imaging and clinical data into insights about patient outcomes to inform clinical trial design.
• Therna Biosciences is using large language model reasoning to connect experimental evidence and RNA medicine design, helping scientists turn biological insights into therapeutic candidates. 

NVIDIA Open Models Streamline Hospital Operations, Expand Access to Specialized Care
Healthcare systems across Europe are working to expand access to specialized care while reducing the administrative demands on already-stretched care teams.

Avelios, Corti, Dedalus, Dawn Health and Sword are also building on NVIDIA Nemotron, powering everything from AI scribes and AI-assisted clinical care to personalized patient support services.

PolyAI is building on NVIDIA Agent Toolkit to speed the path to care through its multilingual dialog deployment with medical software provider Corilus, which has a network spanning more than 70,000 healthcare professionals across Belgium and France.

Apian and VitVio are extending this into the physical world, using NVIDIA Cosmos™ world models and NVIDIA Omniverse™ libraries to build digital twins that monitor and improve hospital operations.

Watch the GTC Berlin keynote from NVIDIA founder and CEO Jensen Huang and explore sessions.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Janette Ciborowski
Corporate Communications
NVIDIA Corporation
press@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; expectations with respect to advances in medicine and life sciences through AI and accelerated computing, including connecting design and experimentation and improving patient care; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on NVIDIA’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, and other NVIDIA product and service names are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries and regions. Other company, product, and service names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08f24e71-de40-4aed-86e2-5e17b88d93bd

News Summary:

• Leading global telecom operators are expanding NVIDIA-powered computing across their networks to deliver advanced services closer to people and businesses, improve wireless experience and automate network operations.
• T-Mobile completes the world’s first AI-RAN call on a commercial network, while BT, Deutsche Telekom and Elisa announce AI-RAN pilots on live networks using Nokia’s CUDA-accelerated anyRAN software on NVIDIA Aerial RAN Computer, and NVIDIA introduces new Aerial RAN Computer configurations for high-capacity sites.
• Nine EMEA telecom operators are building and expanding NVIDIA-powered infrastructure across centralized and distributed locations.
• Operators and software partners are adopting NVIDIA Nemotron open models to deliver agentic services and develop agents for autonomous network operations.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — GTC Berlin — NVIDIA today announced that leading global telecom operators are turning their networks into distributed intelligence platforms, adding NVIDIA accelerated computing to centralized data centers, metro sites and cell sites so they can serve models and applications closer to the people, businesses and machines that use them.

T-Mobile has completed the world’s first AI-RAN call on a live network in Bellevue, Washington, with NVIDIA and Nokia. Deutsche Telekom is advancing physical AI for industries, and Orange is introducing new voice intelligence services for enterprises and emergency responders. Elisa has completed Europe’s first field trial of AI-RAN, running voice, mobile data and vision AI together on a single accelerated computing platform over 5G, and BT is preparing live AI-RAN trials in the U.K. Nokia is bringing its anyRAN software on NVIDIA Aerial RAN Computer (ARC) for trials at BT, Deutsche Telekom, Elisa and Orange.

Nine operators across Europe, the Middle East and Africa (EMEA) are building or expanding NVIDIA-powered infrastructure, while Nokia and Cisco are incorporating NVIDIA Nemotron™ open models into the software operators use to run autonomous networks.

“Telecom networks were built to carry the world’s conversations. Now, they will also carry the world’s intelligence,” said Jensen Huang, founder and CEO of NVIDIA. “Leading global operators are turning their land, power and connectivity into a distributed AI infrastructure — bringing intelligence closer to the industries, people and robots that use it. With Nokia, we’re extending accelerated computing into the radio network itself, creating the foundation for AI-native 5G.”

Intelligence is built in five layers: land, power and shell, chips, infrastructure, models and applications. Telecom operators already own sovereign infrastructure at the first layer, with data centers, regional sites and cell sites that have power, fiber and spectrum.

By adding NVIDIA accelerated computing, open models and applications on top, operators are building the full intelligence stack into their networks. At distributed sites, a common converged platform based on the AI-RAN architecture can serve open models, power robotics, voice and agentic applications, and run intelligent 5G software.

Europe’s Leading Telcos Build Distributed Infrastructure
Infrastructure sits at the foundation of telecom’s transition to distributed service platforms.

Deutsche Telekom plans to expand its NVIDIA-powered Industrial AI Cloud, which hosts open models — including NVIDIA Nemotron and Soofi — and serves robotics companies such as Agile Robots. At distributed sites, Deutsche Telekom is piloting AI-RAN trials with Nokia and NVIDIA, and demonstrating NVIDIA ARC to run inference between the device and the network edge.

A GTC Berlin demonstration with Agile Robots shows the approach: on-robot intelligence handles real-time perception and action, a model at the distributed edge supports fine-tuning and coordination across robots, and the central infrastructure provides capacity for larger training workloads.

Orange is hosting open models, including NVIDIA Nemotron, as a managed service on top of its Live Intelligence trusted AI platform, enabling new advanced services for enterprises. At distributed sites, Orange is deploying NVIDIA ARC for voice intelligence applications using Nemotron Speech, demonstrating new services to help emergency and field services teams translate across multiple languages in real time with low latency and reliability.

Elisa has deployed NVIDIA ARC at a distributed network location, running a voice intelligence application that serves as an enterprise assistant, and is using open models to build edge applications.

EMEA telcos are building or expanding NVIDIA-powered infrastructure:

• New infrastructure: CRA in the Czech Republic, etisalat in the United Arab Emirates, Silknet in Georgia and TIM in Italy.
• Expansions: Cassava in Africa, Deutsche Telekom in Germany, Fastweb + Vodafone in Italy, Kazakhtelecom in Central Asia and Orion Telecom in Serbia.

AI-RAN Brings Accelerated Computing Into the Radio Network
AI-RAN extends accelerated computing into the radio access network (RAN), turning it into an intelligence workload that runs on the same platform as advanced services, so operators can get more out of their spectrum while serving demand from sites close to users.

Globally, nearly 20 telecom operators have publicly announced AI-RAN collaborations using Nokia anyRAN software and NVIDIA ARC.

• T-Mobile recently marked the world’s first AI-RAN call on its commercial network in Bellevue, Washington, running on commercial ARC servers, Nokia’s NVIDIA CUDA-accelerated RAN software and massive multiple-input multiple-output radios, and connected to an existing 5G Standalone core and a commercial smartphone.
• BT is planning live AI-RAN trials in Birmingham, England, with Nokia and NVIDIA in 2027.
• Deutsche Telekom has validated Nokia and NVIDIA’s commercial AI-RAN platform in Bonn and Oulu labs, including AI-enhanced uplink channel estimation to improve uplink user throughput, with plans to move to field trials in 2027.
• Elisa simultaneously ran voice, mobile data and video analytics on the NVIDIA ARC platform, marking a European first in Elisa’s over-the-air field environment using 5G spectrum. The trial clears the way for distributed deployment and commercial AI-RAN services in 2027.
• Orange is testing Nokia 5G software on NVIDIA ARC, focusing on AI-RAN spectral efficiency improvements and support for edge services in live networks.

NVIDIA is introducing two ARC configurations — MGX 2U and MGX 4U — designed for dense, high-capacity intelligence and radio workloads, typically deployed at centralized RAN sites. Powered by NVIDIA RTX PRO™ 6000 Blackwell Server Edition GPUs, the configurations will offer x86 and NVIDIA Vera CPU options. Dell Technologies, Quanta Cloud Technology and Supermicro will offer ARC-ready servers.

Open Models Power Autonomous Network Operations
Leading telcos are using open models and agents to speed progress toward fully autonomous network operations. NVIDIA Nemotron open models and NVIDIA Agent Toolkit software are now integrated into leading partners’ commercial software, powering specialized agents built for telecom network workflows.

Nokia is integrating NVIDIA Nemotron into its Autonomous Networks Suite and using NVIDIA Agent Toolkit software to build and deploy trusted agents that manage operations across fixed, radio, core and transport networks.

Cisco has fine-tuned NVIDIA Nemotron models and integrated them into Crosswork AI, creating a common agentic layer across its Crosswork Network Automation software to manage IP and optical transport networks. The company is also using NVIDIA Agent Toolkit to help telcos operate agents safely.

TCS is working with telcos to fine-tune NVIDIA Nemotron models and use NVIDIA Agent Toolkit to build specialized agents that validate radio-site builds, detect, diagnose and auto-remediate network issues, and deliver multilingual voice experiences. BT is adopting Nemotron to build agents that inspect field-installation photos, detect problems and help reduce repeat site visits.

NTT DATA is extending its NextGenOSS platform with fine-tuned NVIDIA Nemotron models and NVIDIA Agent Toolkit to build agents that detect early network degradation, identify likely root causes and recommend next actions.

Watch the GTC Berlin keynote from Huang and explore sessions.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Olivia Wright
Corporate Communications
NVIDIA Corporation
press@nvidia.com 

Certain statements in this press release including, but not limited to, statements as to: expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners, and related trials, deployments and timing; expectations with respect to technology developments, and related trends and drivers; expectations with respect to the transformation of telecommunications networks into distributed computing platforms and related benefits; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on NVIDIA’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, and other NVIDIA product and service names are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries and regions. Other company, product, and service names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3e77f346-831f-4576-bbb6-04bfc306e4c3

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Blossom Gold Inc. (“Blossom Gold” or the “Company”) (TSX: BGAU) is pleased to announce the appointment of Kappes, Cassiday & Associates (“KCA”) as lead consultant for the Feasibility Study at its Rosebud Open-Pit Project (“Rosebud” or the “Project”) in Pershing County, Nevada. The Feasibility Study is expected to commence in the second quarter of 2027, following the delivery of an updated Mineral Resource Estimate (“MRE”) at the end of the first quarter of 2027. The Company is also pleased to announce progress with permitting activities required for the Project’s Environmental Impact Statement to maintain Blossom Gold’s schedule to advance Rosebud to construction by 2029.

Figure 1: Rosebud Planning Schedule and Expected Timeline to Production

Source: Blossom Gold Inc.

Highlights

• KCA appointed lead Feasibility Study consultant: Reno-based KCA brings more than 50 years of heap leach, metallurgical, engineering and construction experience and is already familiar with Rosebud through its ongoing metallurgical test work on Rosebud metallurgical samples. KCA’s track record includes several major design through construction contacts, including for Agnico Eagle (engineering, procurement and construction management (“EPCM”) the contract for Pinos Altos and EPCM contract for La India), Gammon Lake Resources (EPCM contract for Ocampo) and Pan American Silver (EPCM contract for Dolores), to name a few.
• Full technical team in place for permitting and feasibility: KCA will coordinate feasibility work alongside Northern Lights Mining (resource estimation and mine design), GMining Services (mine geotechnical evaluation and studies), and NewFields MDTS (processing facilities geotechnical evaluation and design). Permitting is coordinated by principal environmental consultant Westland Resources (Federal and State coordination, biological, cultural, tribal engagement) and supported by SRK Consulting (hydrological and geochemical evaluation, studies and monitoring)
• Project Schedule aligned to allow commencement of construction in 2029 with first-production in late-2030, early-2031.

“We chose KCA to lead the Rosebud Feasibility Study because of KCA’s clear enthusiasm to be the lead for Rosebud’s feasibility and, most importantly, KCA does not build facilities that don’t work,” said Graden Colby, Chief Operating Officer of Blossom Gold. “KCA has a track record of taking feasibility studies through to engineering, procurement and construction, as it did at Pinos Altos and La India for Agnico Eagle and at Ocampo for Gammon Lake. Like Agnico and Gammon, that is exactly the standard we want for Rosebud, an owner-operator approach to feasibility with EPCM execution that leads to successful mines. KCA is familiar and works well with our other technical consultants and we look forward to the effort.”

On Track for Updated MRE in Q1:27 and Initiation of Feasibility/EIS in Q2:27

Drilling continues at Rosebud, 26,555m drilled since April with three core and one RC rig conducting expansion and infill drilling from surface. Rehabilitation of decline #2 is on schedule after Small Mine Development LLC (SMD) successfully worked through the one major fault in both declines, a splay off the South Ridge Fault. Timberline Drilling Inc. of Elko, Nevada has been selected as the underground drilling contractor for Rosebud. Drilling is expected to begin in December following establishment of drill stations. The remaining drill program to support the MRE involves an additional 11,585m of surface and 8,232m of underground drilling through Q1:27, for an expected total of over 46,000m of new NI 43-101 information for the updated resource estimate.

While feasibility will formally kick-off in Q2:27 there is and has been preliminary engineering done in support of the overall permitting process, both the Federal Environmental Impact Statement (EIS) and State of Nevada process. Blossom and our consultants have already identified expected water and power requirements, provided planning profiles for ore and waste, established facility layouts and infrastructure corridors. Geotechnical, geochemical and hydrology drilling for the expected open-pit has largely been completed. This work and related studies will feed directly into the feasibility study.

Permitting efforts are on schedule with critical path elements met to date. Annual, required raptor surveys were completed. Rosebud’s initial, humidity cell tests (HCT), considered a long lead element of waste characterization, are underway. Pre-EIS meetings have been held with regulators and interested parties. The Project Area for permitting has been defined and presented to Federal and State regulators. Baseline requirements have been determined and documented. Biological surveys began in September with archeology/culture surveys beginning in October. Blossom’s Tribal, community and government engagement efforts have begun.

Metallurgical testing continues with material going through Rosebud’s assessment process at KCA’s lab, including bottle rolls, columns and additional testing to assess carbon-in-leach, carbon-in-pulp and flotation processing. Column results will begin being reported later in Q4.

“I wish every shareholder could visit site and see what has transpired since we began work in April this year!” said Rick Winters, Chief Executive Officer of Blossom Gold. “There were only two years in Rosebud’s history when there was over 25,000m of drilling, in 1990 under LAC Minerals and 1998 under the Hecla/Newmont JV. With an expected 46,000m of Blossom drilling we are very confident we can meaningfully expand and upgrade our existing NI 43-101 inferred open-pit resource of 70.8Mtons at 0.018opt gold and 0.189opt silver (0.62gAu/t and 6.49gAg/t). Our technical drilling is near completion and all focus is on the next 20,000m of resource expansion and infill drilling. The underground is on track after SMD did a great job getting through the one difficult section of the decline. Timberline Drilling will be generating deposit infill information before you know it. Much is underway and the project is on schedule, but what shareholders should expect is a lot of news flow. Drill results as we execute our surface and underground programs and catch-up on approximately 5,000m of resource core yet to be logged. Metallurgical news with column results beginning in December and continuing there after as well as important project execution updates. With our OTCQX Best Markets listing we will work hard to get the story and value proposition out to a new set of investors that could not participate before. Improving liquidity will benefit all shareholders as we advance Rosebud and pursue our discovery at Kamma.”

About Kappes Cassiday & Associates (KCA)

Based in Reno, Nevada, and providing metallurgical services to the mining industry since 1972, KCA is widely recognized as one of the pioneering firms in precious metals heap leaching. The firm offers an integrated service spanning laboratory test work, feasibility-level engineering, process plant design and construction management, and has evaluated and designed heap-leach projects throughout Nevada, the Americas and internationally. KCA has designed and built more than 70 process plants in over 30 countries.

About Blossom Gold Inc.

Blossom Gold is a Canadian-based precious metals exploration and development company that trades on the TSX under the symbol BGAU and the OTCQX under the symbol BGAUF. Blossom Gold acquired the Rosebud Project in connection with the TSX-listing and will be focused on the exploration and development of the project. The Rosebud Project includes the former Rosebud Mine, where mining was conducted from 1997 through 2000 by the Rosebud Mining Company, a Newmont-Hecla joint venture, using underground mining methods where the mine operated at a cut-off grade of approximately 0.2 opt Au (6.8 gAu/t), when gold prices ranged from US$250 to US$350/oz; with mined material truck-hauled approximately 120 miles to an existing Newmont oxide mill for processing.

The current vision for the Rosebud Project is to evaluate the remaining higher-grade mineralization and the surrounding larger volume of lower grade mineralization as a potential open pit mining operation with on-site, heap-leach processing and recovery of gold and silver. The Rosebud Project currently hosts an Inferred Mineral Resource of 70.755 million tons grading 0.62gAu/t (0.018opt Au) and 6.49gAg/t (0.189opt Ag) for 1.28 million ounces of gold and 13.4 million ounces of silver. The mineral resource estimate was open pit constrained using long term gold and silver prices of US$2,500 and US$35 per ounce respectively. The deposit is open in all directions.

Further details on Blossom and the Rosebud Project, including the technical report titled “Mineral Resource Estimate for the Rosebud Property, Pershing County, NV, USA” by Northern Lights Mining LLC, with a report date of December 17, 2025 and an effective date of November 1, 2025, can be found under the Company’s profile on SEDAR+ at www.sedarplus.com and the Company’s website at www.blossomgold.com.

For further information, please contact:

Brandon Throop
Vice President, Corporate Development & Investor Relations
Direct: 1-647-646-7824
Email: bthroop@blossomgold.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements other than statements of historical facts included in this news release constitute forward-looking information, including but not limited to statements regarding the Company’s plans, prospects and business strategies, including the anticipated timing and scope of the Feasibility Study, the expected timing of an updated Mineral Resource Estimate, the anticipated roles of the Company’s consultants, its drilling programs, permitting, the expected timing of a construction decision and the commencement of production, and its vision regarding the Rosebud Project. Terminology such as “plan”, “expect”, “schedule”, “estimate”, “forecast”, “intend”, “anticipate”, “believe”, “may” or “will” and similar expressions identify forward-looking information. By identifying such information in this manner, Blossom is alerting the reader that such information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Blossom to be materially different from those expressed or implied by such information. In addition, in connection with the forward-looking information contained in this news release, Blossom has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the inability of Blossom to achieve any one or more of the key catalysts on the timeline expected, or at all, and any changes in the development of the business of Blossom, as well as those risk factors more generally set out in Blossom’s AIF, which is available under Blossom’s profile on SEDAR+ at www.sedarplus.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein. Although Blossom believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information are reasonable, undue reliance should not be placed on such information, and no assurance or guarantee can be given that such forward-looking information will prove to be accurate. The forward-looking information contained in this news release is provided as of the date of this news release, and Blossom does not undertake to update any forward-looking information that is contained or referenced herein, except in accordance with applicable Canadian securities laws.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1b39eca1-aedc-49ff-b2d8-49c5385c2f0e
https://www.globenewswire.com/NewsRoom/AttachmentNg/146aac90-5184-48ba-831b-fcf3afa745c4

Munich, Düsseldorf, Germany, Oct. 21, 2026 (GLOBE NEWSWIRE) — Munich, Düsseldorf, October 21, 2026 — MC Services AG, a leading international corporate communications and investor relations firm for life sciences and healthcare, will support BIO-Europe^® 2026 as media partner. Taking place in Cologne, Germany, November 9-11, 2026, MC Services invites international, national and regional media, coordinates interview opportunities with attending biotech and pharma executives and experts, and facilitates background conversations that give journalists direct access to the companies, perspectives and developments shaping the biopharma sector.

“In life sciences, where innovation, investment and partnerships depend on trust and mutual understanding, effective communication goes beyond simply sharing information,” said Anne Hennecke, Managing Partner of MC Services. “At MC Services, we combine deep industry expertise with our extensive international network to bring people, together, facilitate direct dialogue between executives and journalists, and ensure relevant, targeted communication for different stakeholder groups. BIO-Europe^® provides an ideal platform for these valuable personal exchanges, and we are pleased to contribute to making them possible as media partner.”

As host city, Cologne is located in one of Germany’s established life sciences and healthcare hubs. The wider Rhineland region is home to more than 200 healthcare companies, approximately 60 startups, 10 universities, and over 40 hospitals and clinics, forming a strong network of industry, research, innovation, and clinical expertise. Beyond its scientific and economic strengths, Cologne is known for its welcoming spirit and international outlook, offering an inviting setting for networking and collaboration. Adding a distinctly local touch, the conference coincides with the start of Cologne’s famous Carnival season on November 11.

Advancing as a Strategic Forum for Global Biopharma Leaders

In its 32^nd year, BIO-Europe^® is expanding its audience and program, emerging as a global strategic forum for the biopharma industry. The conference will bring together more than 6,000 attendees from across the global life sciences ecosystem to shape strategy, build trusted relationships and advance partnerships across the biopharma value chain.

Highlights include:

• Expanded strategic program: Seven integrated content tracks, including dedicated discussions on clinical development, regulatory strategy and biomanufacturing, alongside a new plenary series addressing the industry’s most pressing challenges.
• The future of biotech financing and dealmaking: Discussions on evolving investment strategies, the sustainability of traditional biotech business models, and new approaches to funding innovation amid continued financing constraints.
• Strengthening Europe’s biotech competitiveness: A dedicated discussion on mobilizing institutional capital, accelerating regulatory pathways and strengthening Europe’s ability to develop and retain life sciences innovation.
• Emerging therapeutic and commercial opportunities: Sessions exploring advances in oncology, including antibody-drug conjugates (ADCs), as well as the investment potential of historically underserved areas such as women’s health and healthy aging.
• Curated networking formats designed to support strategic connections and partnerships across the global biopharma ecosystem.
• For more information about BIO-Europe^® 2026, its program and registration details, please visit the event website.

Organized by Informa Connect, BIO-Europe^® 2026 will bring together the global biopharma decision-making community, including biotech and pharma executives, investors and strategic partners.

About MC Services

MC Services AG is a leading international corporate communications and investor relations firm for life sciences and healthcare. Since 1999, we have worked with pharma, biotech, medtech, and healthcare innovators to strengthen public perception, sharpen strategic positioning, and translate complex scientific innovation into clear, compelling stories. We advise clients in engaging with industry partners, investors, and other key stakeholders while expanding their presence in competitive global markets.

Our team of 40 communications experts with backgrounds in science, finance, journalism, and marketing work from offices in Munich, Düsseldorf, Berlin, London, and Boston. Combining strong European foundations with a truly global perspective, we support clients not only across Europe but also in North America, Asia Pacific, and the Middle East. 

www.mc-services.eu

About Informa Connect

Informa Connect, a division of Informa PLC, creates global platforms where industries connect, learn and collaborate through events, digital services and professional communities. Through its life sciences portfolio, Informa Connect brings together senior executives, investors and strategic partners to exchange insights, build relationships and drive innovation across global markets.

For more information, please visit: https://informaconnect.com/bioeurope/

CONTACT: Contact

MC Services AG
Brittney Sojeva

+49-211-529252-14
BIO-Europe@mc-services.eu

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Beam Global (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for energy storage and security, future of mobility, and smart city infrastructure, today announced that the Dry Creek Rancheria Band of Pomo Indians has deployed five EV ARC™ off-grid, solar-powered electric vehicle (EV) charging systems in California and ordered an ARC Mobility™ Trailer to complement the deployment. Together with the three EV ARC™ systems sold to the Twenty-Nine Palms Band of Mission Indians in Coachella, eight Beam Global EV ARC™ systems are now deployed across these two California-based tribal communities.

Beam Global has previously sold solutions to other tribal communities, including Northwest Indian College serving the Lummi Nation in Washington and the Confederated Tribes of Grand Ronde in Oregon. With 575 federally recognized tribes in the United States, Beam views its growing list of deployments as a significant opportunity to expand its presence in this market particularly because eligible tribal governments can also qualify for direct payments equal to 30% of qualifying investments in eligible clean electricity generation and energy storage under the federal Clean Electricity Investment Credit (Section 48E).

The EV ARC™ systems deployed for the Dry Creek Rancheria Band of Pomo Indians were supported by a California Energy Commission grant to expand EV charging access on tribally owned land. The systems were purchased through Beam Global’s U.S. General Services Administration (GSA) contract.

“Rising prices for gasoline and diesel at the pump, along with increasing costs and pressures on electrical infrastructure caused by AI data centers and the electrification of almost everything, provide yet more reasons why Beam Global’s rapidly deployed off-grid EV charging and emergency power energy infrastructure solutions make so much sense,” said Desmond Wheatley, CEO of Beam Global. “We are delighted to support tribal communities who have such a long and honorable history of husbanding natural resources. We look forward to continuing to grow this segment of our business by enabling Indigenous communities across the country to save money and become increasingly energy independent.”

EV ARC™ systems generate and store their own renewable electricity, using integrated solar panels and store that energy in Beam Global’s proprietary onboard battery storage. This provides EV charging without the need for construction, trenching, a utility grid connection, or electrical permitting. Their self-contained design enables deployment in locations where traditional charging infrastructure may be costly, time-consuming, or difficult to install.

These capabilities can help tribal communities advance energy sovereignty, improve resilience and bring charging infrastructure to remote locations where traditional grid connections may be too expensive, too disruptive, or impossible to establish. The additional ARC Mobility™ Trailer ordered by the Dry Creek Rancheria Band of Pomo Indians will complement the five deployed systems, allowing charging infrastructure to be transported and relocated as needs change.

For more information about Beam Global’s sustainable EV charging solutions, visit www.BeamForAll.com or contact BeamTeam@BeamForAll.com.

About Beam Global

Beam Global is a sustainable technology innovator that develops and manufactures infrastructure products and technologies. The Company operates at the nexus of innovative and reliable energy, transportation and smart city solutions with a focus on sustainable energy infrastructure, rapidly deployed and scalable EV charging solutions, safe energy storage, energy security and intelligent infrastructure. With operations in the U.S., Europe and the Middle East, Beam Global develops, patents, designs, engineers and manufactures unique and advanced technology solutions that power transportation, provide secure sources of electricity, enable smart city services, save time and money, and protect the environment. Beam Global is headquartered in San Diego, CA, with facilities in Yuma, AZ; Broadview, IL; Belgrade and Kraljevo, Serbia; and Abu Dhabi, UAE. Beam Global is listed on Nasdaq under the symbol BEEM. For more information visit BeamForAll.com, LinkedIn, YouTube, Instagram and X.

Forward-Looking Statements

This Beam Global Press Release may contain forward-looking statements. All statements in this Press Release other than statements of historical facts are forward-looking statements. Forward-looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “target,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may,” or other words and similar expressions that convey the uncertainty of future events or results. These statements relate to future events or future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Beam Global’s actual results to be materially different from these forward-looking statements. Except to the extent required by law, Beam Global expressly disclaims any obligation to update any forward-looking statements.

Investor Relations
Luke Higgins
+1 858-261-7646
IR@BeamForAll.com

Media Contact
Lisa Potok
+1 858-327-9123
Press@BeamForAll.com

PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2026.

Third Quarter 2026 Highlights

• Third quarter revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year. Results included an approximate $7 million revenue impact related to flood damage at the Company’s Cincinnati facility.
• Third quarter GAAP earnings per diluted share of $0.19, compared to $(0.07) in the prior year.
• Adjusted earnings per diluted share of $0.59, compared to $0.54 in the prior year.
• Generated operating cash flow of $96.0 million and reduced the consolidated total leverage ratio to 3.8x.
• Subsequent to quarter-end, completed a $2.1 billion debt refinancing that extended debt maturities and enhanced financial flexibility.
• 2026 full-year revenue guidance of $1.634 billion to $1.654 billion and adjusted earnings per share guidance of $2.30 to $2.40, consistent with the outlook provided on October 2, 2026.

“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing,” said Stuart Essig, Chairman and Chief Executive Officer.

“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”                             

Third Quarter 2026 Consolidated Performance

Total reported revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year.

The Company reported GAAP gross margin of 51.0%, compared to 51.5% in the third quarter of 2025. Adjusted gross margin was 61.1%, compared to 62.9% in the prior year.

Adjusted EBITDA for the third quarter of 2026 was $79.8 million, or 19.4% of revenue, compared to $78.5 million, or 19.5% of revenue, in the prior year.

The Company reported GAAP net income of $14.9 million, or $0.19 per diluted share, in the third quarter of 2026, compared to GAAP net loss of $(5.4) million, or $(0.07) per diluted share, in the prior year.

Adjusted net income for the third quarter of 2026 was $46.4 million, or $0.59 per diluted share, compared to $41.6 million, or $0.54 per diluted share, in the prior year.

Third Quarter 2026 Segment Performance

Specialty Surgery (~70% of Revenues)

Total revenues were $304.1 million, representing reported growth of 3.9% and an organic growth of 4.2% compared to the third quarter of 2025. Results were impacted by approximately $7 million related to flood damage at the Company’s Cincinnati facility.

• Sales in Neuro increased 6.5% on an organic basis primarily driven by growth in CereLink®, Certas® Plus, Bactiseal®, DuraSeal® and recovery in cranial perforators.
• Sales in Instruments declined (0.9%) on an organic basis due to order timing.
• ENT sales declined (1.1%), largely due to a low-single digit decline in sinus balloons.

Tissue Reconstruction (~30% of Revenues)

Total revenues were $107.1 million, representing reported and organic decline of (2.2)% compared to the third quarter of 2025. Key drivers for the quarter include:

• Low-single digit decline in wound reconstruction, with strong growth in DuraSorb® and PriMatrix®, offset by declines in MicroMatrix® and Integra Skin.
• Beginning this quarter, we are referring to our Private Label business as Corporate Partnerships, a name that better reflects the nature of these customer relationships. Corporate Partnerships, was approximately flat compared to the third quarter of last year.

Balance Sheet, Cash Flow and Capital Allocation

The Company generated cash flow from operations of $96.0 million in the quarter. Net debt at the end of the quarter was $1.5 billion, and the consolidated total leverage ratio was 3.8x.

As of the end of the quarter, the Company had total liquidity of approximately $559 million, including $311.9 million in cash plus short-term investments and the remainder available under its revolving credit facility.

Debt Refinancing and Enhanced Financial Flexibility

On October 19, 2026, the Company completed a $2.1 billion debt refinancing consisting of a $1.65 billion senior secured credit facility and $450 million aggregate principal amount of 9.5% senior secured notes due 2033. The new credit facility consists of a $600 million Term Loan A, a $600 million revolving credit facility, and a $450 million Term Loan B.

The Company used the proceeds from the refinancing to repay its existing credit facilities and pay related fees and expenses. The transaction extended the Company’s debt maturity profile, enhanced financial flexibility, and supports the Company’s continued focus on cash generation and deleveraging. Additional information regarding the refinancing is available in the Company’s filings with the Securities and Exchange Commission.

Related to the refinancing, the amended debt covenants provide additional near-term covenant capacity by temporarily increasing the Company’s maximum allowable net leverage ratio from its current level followed by scheduled step-downs to 4.25x during 2027. Under the previous covenants the step down for 2027 was to 4.0x. The Company expects the increase in its effective interest rate to be near the high end of the previously communicated 100- to 200-basis-point range.

2026 Revenue and Adjusted Earnings Per Share Guidance

For the fourth quarter of 2026, the Company expects reported revenues in the range of $413 million to $433 million, representing a reported decline of -5.2% to -0.5% and an organic decline of -5.1% to -0.4%. The Company expects adjusted earnings per diluted share in the range of $0.61 to $0.71.

For the full year 2026, the Company expects revenues in the range of $1.634 billion to $1.654 billion representing reported growth of -0.1% to 1.2% and organic growth of -0.3% to 0.9%. The Company expects adjusted earnings per diluted share in the range of $2.30 to $2.40. The Company continues to expect operating cash flow of approximately $190 million to $200 million for the full year. These expectations are consistent with the preliminary results and updated guidance provided on October 2, 2026.

The updated fourth quarter and full-year outlook reflects the expected revenue impact of the Cincinnati disruption, an updated outlook for Tissue Reconstruction performance, and a consistent outlook for Specialty Surgery. The adjusted earnings per diluted share outlook also reflects business interruption insurance recoveries for lost revenue related to the Cincinnati disruption and incremental interest expense associated with the refinancing.

Conference Call and Presentation Available Online

Integra has scheduled a conference call for 8:30 a.m. ET on Wednesday, October 21, 2026, to discuss third quarter 2026 financial results and forward looking financial guidance. The conference call will be hosted by Integra’s senior management team and will be open to all listeners. Additional forward looking information may be discussed in a question and answer session following the call. Integra’s management team will reference a presentation during the conference call, which can be found in the Investor Relations section of the Company’s website at investor.integralife.com. A live webcast will also be available in the Investor Relations section of the Company’s website at investor.integralife.com.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the company’s website following the call.

About Integra

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” “forecast,” “guidance,” “plan,” “anticipate,” “target,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future business, operational and financial performance and the Company’s expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company’s Braintree facility and the relaunch of SurgiMend in the fourth quarter of 2026, and the estimated impact of the flooding event at our Cincinnati, Ohio manufacturing facility (the “Cincinnati facility”), including on our financial condition and results of operations, and our expectations and progress in our recovery efforts, including timing, costs and expected insurance coverage and reimbursements. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: increased geopolitical instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, geopolitical tension and instability, supply chain disruptions, and interest rate and foreign currency rate fluctuations, on the Company’s suppliers, vendors and customers and on the Company’s business and financial condition, results of operations and cash flows; the Company’s ability to execute its financial, strategic and operating plans effectively; the Company’s ability to remediate quality systems violations; difficulties in implementing the Company’s compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs thereof; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; difficulties or delays, including unexpected costs and the availability of insurance coverage and reimbursements, related to the Company’s Cincinnati facility recovery efforts; the failure of the company’s suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company’s products in these markets; the Company’s ability to predict accurately the demand for its products and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward health care cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company’s products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global health care reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra’s Annual Report on Form 10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission.

These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.

Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income.   The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility (the “Braintree transition”); (v) charges related to the flooding of the Company’s Cincinnati, Ohio manufacturing facility, including inventory losses, asset write-offs, remediation costs, plant restart costs and other directly related costs, net of associated insurance reimbursements, as applicable (the “Cincinnati flood and recovery”); (vi) intangible asset amortization expense; (vii) income tax impact from adjustments; and (vii) impairment charges. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to Braintree transition; (iv) EU Medical Device Regulation-related charges; (v) charges related to the Cincinnati flood and recovery; and (vi) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.

The Company has included reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended June 30, 2026 and 2025. The Company has included a reconciliation of GAAP total debt to net debt for the quarters ended June 30, 2026 and December 31, 2025.  

The Company is providing forward-looking guidance regarding organic revenue and adjusted earnings per diluted share but is not providing reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the actual impact of changes in foreign exchange rates and the financial impact and timing of divestitures, acquisitions, integrations, structural optimization, efforts to comply with the EU Medical Device Regulation, and income tax impact from adjustments are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. The unavailable information could have a material impact on GAAP results.

The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company’s financial condition and results of operations.   For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC’s website at   www.sec.gov or on our website at www.integralife.com.  

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

INTEGRA LIFESCIENCES HOLDINGS CORPORATION  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (UNAUDITED)
(In thousands, except per share amounts)
		Three Months Ended September 30,
			2026				2025
Total revenue, net		$	411,182			$	402,062
Costs and expenses:
Cost of goods sold			201,316				195,071
Research and development			21,897				22,456
Selling, general and administrative			165,311				169,046
Intangible asset amortization			3,758				3,728
Goodwill impairment charge			—				—
Total costs and expenses			392,282				390,301
Operating income (loss)			18,900				11,761
Interest income			5,002				4,982
Interest expense			(22,961	)			(22,725	)
Other income (expense), net			14,723				(842	)
Income (loss) before income taxes			15,664				(6,824	)
Provision (benefit) for income taxes			812				(1,420	)
Net income (loss)		$	14,852			$	(5,404	)
Net income (loss) per share
Diluted		$	0.19			$	(0.07	)
Weighted average common shares outstanding			78,577				76,753

The following table presents revenues disaggregated by the major sources for the three months ended September 30, 2026 and 2025 (amounts in thousands):
		Three Months Ended September 30,
			2026		2025	Change
Neurosurgery		$	214,097	$	201,563	6.2%
Instruments			49,662		50,151	(1.0)%
ENT			40,361		40,869	(1.2)%
Total Specialty Surgical			304,120		292,583	3.9%
Wound Reconstruction Solutions			81,529		83,988	(2.9)%
Corporate Partnerships			25,533		25,491	0.2%
Total Tissue Reconstruction			107,062		109,479	(2.2)%
Total Reported Revenues		$	411,182	$	402,062	2.3%
Impact of changes in currency exchange rates			810		—
Total organic revenues(1)		$	411,992	$	402,062	2.5%

(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.

Items included in GAAP net income and location where each item is recorded are as follows:

(In thousands)

Three Months Ended September 30, 2026
Item	Total Amount		COGS(a)	SG&A(b)	R&D(c)		Amort (d)	OI&E(e)		Tax(f)
Acquisition, divestiture and integration-related charges	(3,026	)	82	2,211	(1,322	)	—	(3,997	)	—
Structural Optimization charges	5,742		3,486	1,322	935		—	—		—
EU Medical Device Regulation charges	2,556		297	760	1,499		—	—		—
Braintree Transition	8,772		8,770	1	—		—	—		—
Cincinnati Flood	782		5,709	—	—		—	(4,927	)	—
Intangible asset amortization expense	26,850		23,091	—	—		3,758	—		—
Estimated income tax impact from above adjustments and other items	(10,083	)	—	—	—		—	—		(10,083	)
Depreciation expense	10,287		—	—	—		—	—		—

a) COGS – Cost of goods sold
b) SG&A – Selling, general and administrative
c) R&D – Research & development
d) Amort. – Intangible asset amortization
e) OI&E – Other income & expense
f) Tax – Income tax expense (benefit)

Items included in GAAP net income and location where each item is recorded are as follows:

(In thousands)

Three Months Ended September 30, 2025
Item	Total Amount		COGS(a)	SG&A(b)		R&D(c)		Amort (d)	OI&E(e)	Tax(f)
Acquisition, divestiture and integration-related charges	(6,588	)	177	(6,182	)	(1,029	)	—	445	—
Structural Optimization charges	11,052		8,413	2,786		(146	)	—	—	—
EU Medical Device Regulation charges	10,554		808	5,396		4,350		—	—	—
Braintree Transition	13,957		13,447	510		—		—	—	—
Intangible asset amortization expense	26,873		23,145	—		—		3,728	—
Estimated income tax impact from above adjustments and other items	(8,823	)	—	—		—		—	—	(8,823	)
Depreciation expense	11,289		—	—		—		—	—	—

a)  COGS – Cost of goods sol
b)  SG&A – Selling, general and administrative
c)  R&D – Research & development
d)  Amort. – Intangible asset amortization
e)  OI&E – Other income & expense
f)  Tax – Income tax expense (benefit)

RECONCILIATION OF NON-GAAP ADJUSTMENTS – GAAP NET INCOME TO ADJUSTED EBITDA (UNAUDITED)
(In thousands)
		Three Months Ended September 30,
			2026				2025
GAAP net income (loss)		$	14,852			$	(5,404	)
Non-GAAP adjustments:
Depreciation and intangible asset amortization expense			37,137				38,162
Other (income) expense, net			(5,545	)			842
Interest expense, net			17,706				17,298
Income tax expense			812				(1,420	)
Structural optimization charges			5,742				11,052
EU Medical Device Regulation charges			2,556				10,554
Braintree Transition			8,772				13,957
Cincinnati Flood			782				—
Acquisition, divestiture and integration-related charges			(3,026	)			(6,588	)
Total of non-GAAP adjustments			64,936				83,857
Adjusted EBITDA		$	79,787			$	78,453

RECONCILIATION OF NON-GAAP ADJUSTMENTS – GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE (UNAUDITED)
(In thousands, except per share amounts)
		Three Months Ended September 30,
			2026				2025
GAAP net income (loss)		$	14,852			$	(5,404	)
Non-GAAP adjustments:
Structural optimization charges			5,742				11,052
Acquisition, divestiture and integration-related charges			(3,026	)			(6,588	)
EU Medical Device Regulation charges			2,556				10,554
Braintree Transition			8,772				13,957
Cincinnati Flood			782				—
Intangible asset amortization expense			26,850				26,873
Estimated income tax impact from adjustments and other items			(10,083	)			(8,823	)
Total of non-GAAP adjustments			31,592				47,025
Adjusted net income		$	46,444			$	41,621
Adjusted diluted net income per share		$	0.59				0.54
Weighted average common shares outstanding for diluted net income per share			78,577				76,850

CONDENSED BALANCE SHEET DATA (UNAUDITED)
(In thousands)
		September 30, 2026			December 31, 2025
Short term investments		$	59,669		$	28,693
Cash and cash equivalents			252,261			235,048
Trade accounts receivable, net			248,994			278,849
Inventories, net			464,454			492,735
Current and long-term borrowing under senior credit facility			1,745,388			1,768,306
Borrowings under securitization facility			81,200			87,800
Convertible securities			—			—
Stockholders’ equity		$	1,066,617		$	1,043,463

CONDENSED STATEMENT OF CASH FLOWS (UNAUDITED)
(In thousands)
		Nine Months Ended September 30,
			2026				2025
Net cash provided by operating activities		$	128,582			$	38,568
Net cash (used in) investing activities			(68,377	)			(73,156	)
Net cash (used in) provided by financing activities			(38,809	)			3,993
Effect of exchange rate changes on cash and cash equivalents			(4,183	)			16,406
Net increase (decrease) in cash and cash equivalents		$	17,213			$	(14,189	)

RECONCILIATION OF NON-GAAP ADJUSTMENTS – GAAP OPERATING CASH FLOW TO MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION (UNAUDITED)
(In thousands)
		Three Months Ended September 30,
			2026			2025
Net cash provided by operating activities		$	95,977		$	40,907
Purchases of property and equipment			(10,246	)		(15,156	)
Free cash flow		$	85,731		$	25,751
Adjusted net income(1)		$	46,444		$	41,621
Adjusted free cash flow conversion			184.6	%		61.9	%
		Twelve Months Ended September 30,
			2026			2025
Net cash provided by operating activities		$	140,397		$	89,315
Purchases of property and equipment			(54,615	)		(93,821	)
Free cash flow		$	85,782		$	(4,506	)
Adjusted net income(1)		$	195,456		$	180,896
Adjusted free cash flow conversion			43.9	%	(2.5)        %

(1) Adjusted net income for quarters ended September 30, 2026 and 2025 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.

The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.

RECONCILIATION OF NON-GAAP ADJUSTMENTS – NET DEBT CALCULATION (UNAUDITED)
(In thousands)
		September 30, 2026			December 31, 2025
Short-term borrowings under senior credit facility		$	48,438		$	38,750
Long-term borrowings under senior credit facility			1,696,950			1,729,556
Borrowings under securitization facility			81,200			87,800
Convertible securities			—			—
Deferred financing costs netted in the above			2,112			3,257
Short term investments			(59,669	)		(28,693	)
Cash & Cash Equivalents			(252,261	)		(235,048	)
Net Debt		$	1,516,770		$	1,595,622

RECONCILIATION OF NON-GAAP ADJUSTMENTS – GAAP GROSS PROFIT TO MEASURES OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN (UNAUDITED)
(In thousands, except percentages)
		Three Months Ended September 30,
			2026				2025
Total revenues, net		$	411,182			$	402,062
Cost of goods sold			201,316				195,071
Reported Gross Profit			209,866				206,991
Cincinnati Flood			5,709				—
Structural optimization charges			3,486				8,413
Acquisition, divestiture and integration-related charges			82				177
Braintree Transition			8,770				13,447
EU Medical Device Regulation			297				808
Intangible asset amortization expense			23,091				23,145
Adjusted Gross Profit		$	251,302			$	252,981
Total Revenues		$	411,182			$	402,062
Adjusted Gross Margin			61.1	%			62.9	%

Deutsche Lufthansa AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

21. Oct 2026 / 11:54 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Legal entity

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

Platform Brings Together NVIDIA Vera Rubin, Vera CPUs and BlueField-4 to Power Enterprise Infrastructure to Build, Run, Observe and Enforce Safe Agents at Industrial Scale

News Summary:

• The NVIDIA OpenShell Reference Architecture delivers enterprise governance, isolation and security for building, containing, observing and enforcing safe agents across enterprise infrastructure and edge systems.
• Built on the foundation of NVIDIA OpenShell secure runtime software, the architecture brings together NVIDIA Vera Rubin infrastructure for model inference, NVIDIA Vera CPUs for agent harnesses and tool use, and NVIDIA BlueField-4 DPUs running NVIDIA Sentry for in-silicon enforcement. The OpenShell Reference Architecture extends to the edge with NVIDIA RTX Spark, NVIDIA DGX Spark and NVIDIA DGX Station systems.
• The OpenShell Reference Architecture runs on leading enterprise operating systems, including Canonical, Red Hat, and Microsoft Windows and Microsoft Execution Containers.
• Anthropic, AWS, Cisco, CrowdStrike, Dassault Systèmes, Dell Technologies, Google Cloud, HPE, IBM, Meta, Microsoft, OpenAI, Palo Alto Networks, Perplexity, SAP, ServiceNow, Siemens, SpaceX Super Intelligence and others are among those working with the OpenShell Reference Architecture to enhance the security of agent deployments.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — GTC Berlin — NVIDIA today announced the NVIDIA OpenShell Reference Architecture, which enables building, containing, observing and enforcing safe agents on enterprise infrastructure and edge systems.

The OpenShell Reference Architecture builds on the foundation of NVIDIA OpenShell™ secure runtime software, extending it into full-stack, industrial-scale infrastructure for agent development and operations.

It includes NVIDIA Vera Rubin infrastructure for running enterprise workloads, including closed and open models built with NVIDIA Nemotron™; NVIDIA Vera CPUs for operating agent harnesses; open source NVIDIA OpenShell software; and NVIDIA BlueField^® DPUs for running the NVIDIA Sentry unified security software framework that provides continuous out-of-band monitoring of agent behavior and in-silicon policy enforcement.

The OpenShell Reference Architecture is extensible to agents running at the edge across industries such as retail, healthcare, manufacturing, robotics, software development and telecommunications with NVIDIA RTX Spark™, NVIDIA DGX Spark™ and NVIDIA DGX Station™ systems.

“AI capability and safety must advance together,” said Jensen Huang, founder and CEO of NVIDIA. “As enterprises prepare to deploy billions of AI agents, safety and control must be built into the computing architecture. NVIDIA created OpenShell to give agents the freedom to do useful work within clearly defined boundaries — contained, monitored and under control. With the OpenShell Reference Architecture, agents can think on Rubin, act on Vera and be governed on BlueField.”

Full-Stack Infrastructure Built for Agents
The OpenShell Reference Architecture features NVIDIA accelerated computing paired with software for secure agent operations.

• NVIDIA Vera Rubin, with NVIDIA Vera Rubin NVL72 infrastructure at its core, is fungible across pretraining, post-training and inference. For agentic workloads, NVIDIA Vera Rubin NVL72 systems deliver 30x higher throughput per megawatt.
• NVIDIA Vera CPUs deliver 2x the performance of x86 processors with greater energy efficiency and run NVIDIA OpenShell, which provides a secure runtime boundary for autonomous agents.
• NVIDIA BlueField-4 DPUs continuously monitor agent behavior with NVIDIA Sentry, built on NVIDIA DOCA™ software. BlueField and NVIDIA Sentry together provide in-silicon security enforcement — if an agent attempts to move outside its software boundary, NVIDIA Sentry quarantines and stops it in milliseconds. NVIDIA Sentry, powered by DOCA and running on BlueField-4, boosts agent capacity by up to 20%.

NVIDIA Partners Building Secure Agent Deployments With OpenShell
NVIDIA is working with industry leaders building infrastructure, models and software to enable industries to safely deploy agents in production.

The OpenShell Reference Architecture runs on leading enterprise operating systems and container orchestration layers, including Linux and Kubernetes infrastructure powered by Canonical, SUSE and Red Hat, as well as Microsoft Windows using Microsoft Execution Containers (MXC). It can run on cloud operating systems from Amazon Web Services, Google Cloud and Microsoft Azure.

Enterprises can run agents from model builders including Anthropic, Cohere, Google, Meta, OpenAI, Perplexity, Reflection and SpaceX Super Intelligence on OpenShell infrastructure. NVIDIA is also working with model builder partners on OpenShell deployments for advanced model research.

Cybersecurity leaders 1Password, Check Point, CrowdStrike, Cisco, F5, Fortinet, Microsoft, Okta, Palo Alto Networks, TrendAI and Zscaler are integrating support for the OpenShell Reference Architecture into their agent security solutions.

Leading banks — including Europe’s BBVA and Santander — are working with NVIDIA to explore the OpenShell Reference Architecture as a framework for strengthening agent safety, security and governance.

Enterprise software leaders Cadence, Dassault Systèmes, IBM, SAP, Siemens and Synopsys are working with OpenShell to build agent software platforms. Palantir and NVIDIA are working with customers to deploy secure agents in production.

SAP is integrating the NVIDIA OpenShell Reference Architecture with Joule Studio runtime, part of SAP Business AI Platform, connecting business governance with secure agent execution.

ServiceNow today announced the general availability of ServiceNow Arc, a personal long-running AI agent with actions governed at runtime by the ServiceNow Super Intelligence Control Tower and enforced by NVIDIA OpenShell. In addition, ServiceNow’s recently announced AI Passport authority layer carries those policies to NVIDIA OpenShell and NVIDIA Sentry, so enterprises can revoke an AI agent’s access across software and hardware within seconds.

NVIDIA system manufacturers Dell Technologies, Cisco, HPE, Lenovo and Supermicro are among those building infrastructure with the OpenShell Reference Architecture.

NVIDIA is also working with cloud service providers including CoreWeave, Crusoe, Firebird, Firmus, GMI Cloud, IREN, Lambda, Nebius, Nscale, Oracle Cloud Infrastructure and Vultr to deploy OpenShell-ready infrastructure.

Inference and post-training service providers including Baseten, Deepinfra, Fireworks and Together AI are building OpenShell Reference Architecture integrations into their model development pipelines.

Availability
The NVIDIA OpenShell Reference Architecture is now available.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Corporate Communications
NVIDIA Corporation
press@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners, and related deployments, availability and timing; expectations with respect to technology developments, and related trends and drivers; expectations with respect to enterprise adoption and deployment of AI agents and related safety, governance and control; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on NVIDIA’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, and other NVIDIA product and service names are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries and regions. Other company, product, and service names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/077e35f0-622d-4f90-8402-6f2bce21a913

FREUDENSTADT, Germany, Oct. 21, 2026 (GLOBE NEWSWIRE) — SCHMID Group N.V. (NASDAQ: SHMD) (the “Company” or “SCHMID”), a global leader in providing solutions for the electronics industry, today provided the following operational update following the completion of the third quarter of 2026.

Operational Update for the third quarter ended September 30, 2026

In the third quarter of 2026, the Company recorded order intake of €67.8 million and reported preliminary revenues of €24.0 million. Order intake in the third quarter more than doubled compared with the second quarter of 2026 (€30.7 million) and includes the repeat order exceeding €37 million announced on July 7, 2026. Cumulative order intake for the first nine months of 2026 amounts to €111.7 million, and revenues for the first nine months amount to €70.0 million.

The order backlog stood at €96.8 million as of September 30, 2026, compared with €54.8 million as of June 30, 2026. Order intake and order backlog figures relate exclusively to orders for equipment and do not include orders associated with services or spare parts.

Order momentum continuing into the fourth quarter

In a separate press release issued today, SCHMID announced that it has reached an agreement with one of its key customers and long-standing technology partner on an equipment order of more than €25 million to support the expansion of advanced High-Density Interconnect (HDI) manufacturing capacity in Malaysia. Of this order, more than €7 million was already included in order intake for the third quarter of 2026 with the remainder recorded as order intake in the fourth quarter of 2026.

Full-year 2026 guidance for order intake increased

For the full-year 2026, management confirms its guidance of revenues of more than €100 million and an Adjusted EBITDA margin of 6 to 9% (based on Adjusted EBITDA as defined in the Company’s press release dated August 25, 2026). Management increases its order intake guidance of from a range of €125 to €150 million to more than €150 million. The savings from our ‘Sprint’ I efficiency program progress as planned and “Sprint II” material cost savings program is showing first results.

Preliminary information and non-IFRS measures

The financial information presented in this press release for the third quarter of 2026, the first nine months of 2026 and the guidance for the full-year 2026 is preliminary and unaudited. Actual results may differ from the preliminary estimates presented herein. Order intake and order backlog are operational metrics used by management to evaluate the Company’s business activity and visibility of future revenue. These metrics are not measures defined under International Financial Reporting Standards (“IFRS”) and may not be comparable to similarly titled measures used by other companies.

Adjusted EBITDA is a non-IFRS financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, adjusted to exclude certain non-recurring or non-operational items. Because Adjusted EBITDA excludes items that may be included in the most directly comparable IFRS measure, investors should not consider Adjusted EBITDA in isolation or as a substitute for measures prepared in accordance with IFRS. The Company is unable to provide a reconciliation of forward-looking Adjusted EBITDA guidance to the most directly comparable IFRS financial measure without unreasonable effort because certain items that impact such measures are uncertain, out of the Company’s control and cannot be reasonably predicted.

Forward-looking Statements

This press release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s preliminary third quarter and first nine months of 2026 results, financial outlook for fiscal year 2026, expected order intake and revenue growth, anticipated demand trends, and other statements that are not historical facts. There are a significant number of factors that could cause actual results to differ materially from the statements made in this press release. Additional risks and uncertainties that could affect our financial results are included under “Item 3. Key Information – 3.D. Risk Factors” in our annual report on Form 20-F filed with the SEC on May 15, 2026, which is available on the SEC’s website at www.sec.gov. Additional information will also be set forth in other filings that we make with the SEC from time to time. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable law.

About the SCHMID Group

The SCHMID Group is a global leader in providing advanced equipment and process solutions for the high-tech industry, with a strong focus on electronics and semiconductor-related applications. Headquartered in Freudenstadt, Germany, and founded in 1864, SCHMID employs more than 800 people worldwide and operates technology centers and manufacturing facilities in Germany and China, as well as sales and service locations globally.

SCHMID develops customized systems and process solutions for the production of substrates, printed circuit boards and other electronic components. Its portfolio addresses a range of high-growth applications, including advanced packaging, semiconductor-related technologies, AI-driven electronics, printed circuit boards, substrates and glass-based technologies.

SCHMID’s solutions enable customers to achieve high technology levels, high yields, low production costs, maximum efficiency, quality, and sustainability in advanced manufacturing processes.

For more information about the SCHMID Group, please visit www.schmid-group.com or contact investor-relations@schmid-group.com.

Contact
Press@schmid-group.com